

| Multiple linear regression Tabular results | | A | B | C | D | E | F | G |
|---|--------------------------------|--------------------------------|-----------------|----------------------|----------------------------|----------------|----------------|---------------------|
| | | Data Set-A | Data Set-B | Data Set-C | Data Set-D | Data Set-E | Data Set-F | Data Set-G |
| | | Y | Y | Y | Y | Y | Y | Y |
| 1 | Table Analyzed | Data 1 | | | | | | |
| 2 | Dependent variable | Patent filing to NDS | | | | | | |
| 3 | Regression type | Least squares | | | | | | |
| 4 | | | | | | | | |
| 5 | Model | | | | | | | |
| 6 | Analysis of Variance | SS | DF | MS | F (DFn, DFd) | P value | | |
| 7 | Regression | 92.77 | 6 | 15.46 | F (6, 103) = 1.446 | P=0.2045 | | |
| 8 | Biologic vs small molecule | 1.328 | 1 | 1.328 | F (1, 103) = 0.1242 | P=0.7253 | | |
| 9 | Orphan | 10.39 | 1 | 10.39 | F (1, 103) = 0.9710 | P=0.3267 | | |
| 10 | First in class | 41.81 | 1 | 41.81 | F (1, 103) = 3.909 | P=0.0507 | | |
| 11 | Outcome | 3.034 | 1 | 3.034 | F (1, 103) = 0.2837 | P=0.5954 | | |
| 12 | ATC - antineoplastics vs other | 22.51 | 1 | 22.51 | F (1, 103) = 2.104 | P=0.1499 | | |
| 13 | Log of trial size | 0.03067 | 1 | 0.03067 | F (1, 103) = 0.002868 | P=0.9574 | | |
| 14 | Residual | 1102 | 103 | 10.70 | | | | |
| 15 | Total | 1194 | 109 | | | | | |
| 16 | | | | | | | | |
| 17 | Parameter estimates | Variable | Estimate | Standard erro | 95% CI (asymptotic) | t | P value | P value summ |
| 18 | β_0 | Intercept | 11.33 | 1.691 | 7.978 to 14.68 | 6.702 | <0.0001 | **** |
| 19 | β_1 | Biologic vs small molecule | -0.2449 | 0.6950 | -1.623 to 1.133 | 0.3524 | 0.7253 | ns |
| 20 | β_2 | Orphan | -0.8318 | 0.8441 | -2.506 to 0.8423 | 0.9854 | 0.3267 | ns |
| 21 | β_3 | First in class | -1.448 | 0.7321 | -2.900 to 0.004420 | 1.977 | 0.0507 | ns |
| 22 | β_4 | Outcome | -0.3760 | 0.7060 | -1.776 to 1.024 | 0.5326 | 0.5954 | ns |
| 23 | β_5 | ATC - antineoplastics vs other | 1.184 | 0.8163 | -0.4348 to 2.803 | 1.451 | 0.1499 | ns |
| 24 | β_6 | Log of trial size | -0.03259 | 0.6086 | -1.240 to 1.174 | 0.05355 | 0.9574 | ns |
| 25 | | | | | | | | |
| 26 | Goodness of Fit | | | | | | | |
| 27 | Degrees of Freedom | 103 | | | | | | |
| 28 | R squared | 0.07768 | | | | | | |
| 29 | | | | | | | | |
| 30 | Multicollinearity | Variable | VIF | R2 with other | | | | |
| 31 | β_0 | Intercept | | | | | | |
| 32 | β_1 | Biologic vs small molecule | 1.109 | 0.09816 | | | | |
| 33 | β_2 | Orphan | 1.759 | 0.4314 | | | | |

| Multiple linear regression Tabular results | | A | B | C | D | E | F | G |
|---|---------------------------------|--------------------------------|----------------|-------------------------|------------------------|------------|------------|------------|
| | | Data Set-A | Data Set-B | Data Set-C | Data Set-D | Data Set-E | Data Set-F | Data Set-G |
| | | Y | Y | Y | Y | Y | Y | Y |
| 34 | β_3 | First in class | 1.094 | 0.08551 | | | | |
| 35 | β_4 | Outcome | 1.281 | 0.2194 | | | | |
| 36 | β_5 | ATC - antineoplastics vs other | 1.359 | 0.2644 | | | | |
| 37 | β_6 | Log of trial size | 1.553 | 0.3561 | | | | |
| 38 | | | | | | | | |
| 39 | Normality of Residuals | Statistics | P value | Passed normality | P value summary | | | |
| 40 | Anderson-Darling (A2*) | 0.2938 | 0.5945 | Yes | ns | | | |
| 41 | D'Agostino-Pearson omnibus (K2) | 0.9663 | 0.6168 | Yes | ns | | | |
| 42 | Shapiro-Wilk (W) | 0.9913 | 0.7116 | Yes | ns | | | |
| 43 | Kolmogorov-Smirnov (distance) | 0.05664 | >0.1000 | Yes | ns | | | |
| 44 | | | | | | | | |
| 45 | Data summary | | | | | | | |
| 46 | Rows in table | 113 | | | | | | |
| 47 | Rows skipped (missing data) | 3 | | | | | | |
| 48 | Rows analyzed (# cases) | 110 | | | | | | |
| 49 | Number of parameter estimates | 7 | | | | | | |
| 50 | #cases/#parameters | 15.7 | | | | | | |